American Century Companies Inc. Has $748.50 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

American Century Companies Inc. trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,641,441 shares of the biopharmaceutical company’s stock after selling 152,405 shares during the period. Alnylam Pharmaceuticals comprises about 0.4% of American Century Companies Inc.’s investment portfolio, making the stock its 21st largest holding. American Century Companies Inc. owned about 1.24% of Alnylam Pharmaceuticals worth $748,500,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ALNY. Root Financial Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. Atlantic Union Bankshares Corp bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $30,000. ORG Partners LLC raised its holdings in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 33 shares during the period. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $36,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.5%

ALNY stock opened at $332.92 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The business’s fifty day moving average price is $360.54 and its two-hundred day moving average price is $418.95. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The stock has a market capitalization of $44.15 billion, a price-to-earnings ratio of 194.69 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the firm earned ($0.65) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% compared to the same quarter last year. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Canaccord Genuity Group increased their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Morgan Stanley dropped their target price on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research report on Friday, January 30th. Raymond James Financial restated an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Stifel Nicolaus lifted their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,959 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the transaction, the executive vice president owned 31,769 shares in the company, valued at approximately $9,850,931.52. This trade represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,041 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total transaction of $677,530.36. Following the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $7,058,797.44. This represents a 8.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,578 shares of company stock valued at $12,416,105 over the last ninety days. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.